Pan-European arthritis treatment brief heads to 90TEN Healthcare

90TEN Healthcare has won duties on the two-year rollout of a biopharmaceutical treatment for arthritis across Europe.

90TEN senior account director James Osborn: will lead the account
90TEN senior account director James Osborn: will lead the account

Inflectra is made by pharma company Hospira and is one of the first two examples of a medicine known as a monoclonal-antibody biosimilar.

A biosimilar is a close copy of a biological medicine that has already been authorised for use, in this case Remicade.

The first biosimilar was approved in Europe in 2006. According to the European Medicines Agency, Inflectra is the first time the biosimilar concept has been applied successfully to such a complex molecule as a monoclonal antibody.

Hospira, which awarded the account to 90TEN following a competitive pitch, has done limited comms work on biosimilars in Europe.

Senior account director James Osborn, who will lead the account, said: ‘A vital part of our role will be to drive engagement around how Hospira’s offering can help relieve some of the challenges faced by Europe’s healthcare systems.’

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.